medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 4

<< Back Next >>

Ann Hepatol 2012; 11 (4)

Transforming growth factor α immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue

Pannain VL, Morais JR, Damasceno-Ribeiro O, Avancini-Alves V

Language: English
References: 36
Page: 495-499
PDF size: 87.83 Kb.


ABSTRACT

Background. Transforming growth factor alpha (TGFα) is an important mitogen that binds to epidermal growth factor receptor and is associated with the development of several tumors. Aims. Assessment of the immunoexpression of TGFα in hepatocellular carcinoma (HCC) and in non-neoplastic liver tissue and its relationship to morphological patterns of HCC. Material and methods. The immunohistochemical expression of TGFα was studied in 47 cases of HCC (27 multinodular, 20 nodular lesions). Five lesions measured up to 5 cm and 15 lesions above 5 cm. Thirty-two cases were graded as I or II and 15 as III or IV. The non-neoplastic tissue was examined in 40 cases, of which 22 had cirrhosis. HBsAg and anti-HCV were positive in 5/38 and 15/37 patients, respectively. The statistical analysis for possible association of immunostaining of TGFα and pathological features was performed through chi-square test. Results. TGFα was detected in 31.9% of the HCC and in 42.5% of the non-neoplastic. There was a statistically significant association between the expression of TGFα and cirrhosis (OR = 8.75, 95% CI = [1.93, 39.75]). The TGFα was detected more frequently in patients anti-HCV(+) than in those HBsAg(+). The immunoexpression of TGFα was not found related to tumor size or differentiation. In conclusion the TGFα is present in hepatocarcinogenesis in HBV negative patients. Further analysis is needed to examine the involvement of TGFα in the carcinogenesis associated with HCV and other possible agents. In addition, TGFα has an higher expression in hepatocyte regeneration and proliferation in cirrhotic livers than in HCC.


REFERENCES

  1. Theise ND, Curado MP, Franceschi S, Hytiroglou P, Kudo M, Park YN, Sakamoto M, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds.). WHO classification of tumours of the digestive system. 4th. Ed. Lyon: IARC; 2011, p. 205-16.

  2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42: S206-S214.

  3. Saffroy R, Pham P, Lemoine A, Debuire B. Biologie moléculaire et carcinome hépatocellulaire:données actuelles et développements futurs. Ann Biol Clin 2004; 62: 649-55.

  4. Fassio E, Díaz S, Santa C, Reig ME, Martínez Artola Y, Alves de Mattos A, Míguez C, et al. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter international study. Ann Hepatol 2010; 9: 63-9.

  5. International consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-64.

  6. Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and noncirrhotic patients? Braz J Med Biol Res 2009; 42: 958-62.

  7. Nascimento C, Bottino A, Nogueira C, Pannain V. Analysis of morphological variables and arterialization in the differential diagnosis of hepatic nodules in explanted cirrhotic livers. Diagn Pathol 2007; 2: 51.

  8. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-42.

  9. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocelular carcinoma. Nat Genet 2002; 31: 339-46.

  10. Kitisin K, Pishvaian MJ, Johnson LB, Mishra L. Liver stem cells and molecular signaling pathways in hepatocellular carcinoma. Gastrointest Cancer Res 2007; 1 (Suppl. 2): 13-21.

  11. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007; 3: 241-7.

  12. Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010; 31: 1409-20.

  13. Calvisi DF, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005; 33: 181-4.

  14. Baek JY, Morris SM, Campbell J, Fausto N, Yeh MM, Grady WM. TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. Int J Cancer 2010; 127: 1060-71.

  15. Mead J E, Fausto N. Transforming growth factor a may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Sci USA 1989; 86: 1558-62.

  16. Fartoux L, Debois-Mouthon C, Poupon R, Rosmorduc O. Thérapie anti-EGFR: vers un ciblage “a la carte” du carcinome hepatocellulaire. Gastroenterol Clin Biol 2006; 30: 1133-5.

  17. Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010; 42S: 264-72.

  18. Collier JD, Guo K, Gullick WJ, Bassendine MF, Burt AD. Expression of transforming growth factor alpha in human hepatocellular carcinoma. Liver 1993; 13: 151-5.

  19. Hsia CC, Axiotis CA, Di Bisceglie AM, Tabor E. Transforming growth factor alpha in human hepatocellular carcinoma and coexpression with Hepatitis B surface antigen liver. Cancer 1992; 70: 1049-56.

  20. Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less differentiated tumor within or adjacent to hepatocellular carcinoma. Relative expression of transforming growth factor a and its receptor in the different areas of tumor. Human Pathol 1995; 26: 1126-32.

  21. Nalesnik LA, Lee RG, Carr BI. Transforming growth factor alpha (TGF) in hepatocellular carcinomas and adjacent hepatic parenchyma. Human Pathol 1998; 29: 228-34.

  22. Zhang J, Wang WL, Li Q, Qiao Q. Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol 2004; 10: 830-3.

  23. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer 1952; 7: 462-503.

  24. Todaro GJ, Fryling C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with the epidermal growth factor receptors. Proc Natl Acad Sci USA 1980; 77: 5258-62.

  25. Twardzik DR. Differential expression of transforming growth factor α during prenatal development of the mouse. Cancer Res 1985; 45: 5413-6.

  26. Liu C, Tsao M-S, Grisham JW. Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res 1988; 48: 850-5.

  27. Masuhara M, Yasunaga M, Tanigawa K, Tamura F, Yamashita S, Sakaida I, Okita K. Expression of hepatocyte growth factor, transformining growth factor α, and transforming growth factor β1 messenger RNA in various human liver disease and correlation with hepatocyte proliferation. Hepatology 1996; 24: 323-9.

  28. Yeh J, Yeh YC. Transforming growth factor-alpha and human cancer. Biomed Pharmacother 1989; 43: 651-9.

  29. Doraiswamy V, Parrot JA, Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. Biol Reproduction 2000; 63: 789-96.

  30. Tanaka S, Imanishi K, Yoshihara M, Haruma K, Sumii K, Kajiyama G, Akamatsu S. Immunoreactive transforming growth factor a is commonly present in colorectal neoplasia. Am J Pathol 1991; 139: 123-9.

  31. Chuang L-Y, Tsai J-H, Yeh Y-C, Chang C-C, Yeh H-W, Guh J-Y, Tsai J-F. Epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma. Hepatology 1991; 13: 1112-6.

  32. Tomiya T, Fujiwara K. Serum transforming growth factor α level as a marker of hepatocellular carcinoma complicating cirrhosis. Cancer 1996; 77: 1056-60.

  33. Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE. The expression of transforming growth factor- alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Am J Surg Pathol 2007; 31: 681-9.

  34. Chung YH, Kim JA, Song BC, Lee GC, Koh MS, Lee YS, Lee SG, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000; 89: 977-82.

  35. Tanaka S, Takenaka K, Matsumata T, Mori R, Sugimachi K. Hepatitis C virus replication is associated with expression of transforming growth factor-a and insulin-like growth factor-II in cirrhotic liver. Dig Dis Sci 1996; 42: 208-15.

  36. Kiss A, Wang N-J, Xie J-P, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-a/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-b receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059-66.




2020     |     www.medigraphic.com